AstraZeneca has marked the completion of the construction of its new advanced medicine manufacturing facility with a site visit by local MP, David Rutley.
During his Covid-secure visit, Mr Rutley met representatives from the 325-strong construction and engineering teams who have been involved in delivering the multi-million pound facility so far.
The advanced medicines manufacturing facility will eventually replace older assets on the AstraZeneca Macclesfield campus, and provide the capacity to meet demand for Zoladex, the pharmaceuticals firm’s oncology medicine, used to treat prostate and breast cancer, and gynaecological disorders.
Chris Maddock, Macclesfield Campus Lead said:
The AZ team and our partners have come together brilliantly over the past two years, working over 500,000 person hours to date. We are incredibly proud that Macclesfield is the home of Zoladex manufacturing, a complex medicine that continues to help millions of patients around the world. The new facility means we will be able to help even more.”
David Rutley MP said:
“Congratulations to everyone involved at AZ, and to their construction and engineering partners, who have reached this important milestone for the new manufacturing facility in the most challenging of circumstances. This is good news for all those work at the Macclesfield site, the local economy and for many patients throughout the world.”